Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

New residences open on Bloemfontein Campus
2013-01-21

 

Photo: Johan Roux
21 January 2013



Beginning 2013, the Bloemfontein Campus is seeing the opening of two new residences where male and female students will be housed under one roof but in separate units. Each residence will house 250 students.

House ConLaurês and House Outeniqua were opened for their first-years and Residence Committee (RC) on Friday 18 January 2013. The two newly Residence Heads, Mr Frank Makhabane (ConLaurês) and Mrs Leani Wimble (Outeniqua) welcomed the new residents.

The uniqueness of these residences is that they will be the first co-ed residences on campus. These residences are wheel chair friendly with fully equipped disabled rooms available. All signage has also been done in Braille. Each floor of the new residences has two lounges, as well as a fully fitted kitchen.

The Prime of House ConLaurês, Sherilyn Roelofse, says, “We aim to create a living space that is holistic and welcoming and will allow our residence members to be able to excel in a number of things”. Sherilyn says ConLaurês comes from the word “Condo Laurus”, which means dreams of victory. The House’s slogan is “The Symphony of Dreams”. Students came up with the name for the residence.

Tsatsi Mokoena, RC member responsible for RAG at House ConLaurês says RC members have been working hard for the past few months, trying to imagine how to do things without a physical structure. ConLaurês will be a residence with an inspirational living space where each student feels welcome, respected for who they are and at home, so that they will have the confidence to follow their dreams.”

The Prime of Outeniqua, Vusumzi Mesatywa says, “Change is always welcome and that is the mindset that we will be embracing as the new residences. When a student graduates, we need them to graduate not only as academics, but also as humans, holistic beings”.

Marla Stanier, RC First-Year Mentor at Outeniqua, says that new experiences await every student that walks through the doors of the residence. “As excited as we are, this new experience will test us in many ways.However, if we stand together as one, we will succeed.”

Mr Quintin Koetaan, Director of Housing and Residence Affairs, says, “The opening of ConLaurês and Outeniqua is a dream come true, providing accommodation for a new generation of students in the 21st Century”.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept